We were delighted to talk to Hyun C Chung (Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea) around the findings from his study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors (Clinical Trial Identifier: NCT03797326).
The abstract ‘LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort.’ (ABSTRACT NUMBER: 230) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
- Could you tell us a little about the aims and design of the LEAP-005 study? (0:05)
- What have been the efficacy and safety findings of the study to date? (1:37)
- On the basis of these findings, how will the study proceed? (3:32)
Disclosures: Hyun C Chung discloses Grant/Research Support from Lilly, GSK, MSD, Merck-Serono, BMS/Ono, Taiho, Amgen, Beigene, Incyte and Zymework; Honoraria from Merck-Serono and Lilly; Consultation for Taiho, Celltrion, MSD, Lilly, BMS, Merck-Serono, Gloria, Beigene, Amgen and Zymework.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
Share this Video
Related Videos In Gastrointestinal Oncology
Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Jean-Luc Van Laethem, ASCO GI 2021: Pembrolizumab for Advanced Hepatocellular Carcinoma
We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) around pembrolizumab therapy in patients with previously untreated advanced hepatocellular carcinoma (Clinical Trial Identifier: NCT02702414). The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!